Eam Investors, LLC Altimmune, Inc. Transaction History

Eam Investors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.14 - $11.62 $121,372 - $659,039	56,716 New	56,716 $638,000
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $116,260 - $244,179	10,896 Added 5.61%	205,167 $2.62 Million
Q2 2022 Aug 12, 2022	BUY	$3.94 - $11.77 $765,427 - $2.29 Million	194,271 New	194,271 $2.27 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.